CDKN2A and lung carcinoma: For Patient 2, we discovered a mutation in CDKN2A, frequently inactivated in lung cancer.26 Patients 3 and 4 both exhibited mutations—distinct for each patient—in FGFR3, reported mutated with a frequency of up to 3% in NSCLC.26 Patient 4 also had a mutation in ABL1, reported mutated with a frequency of 1.5% of NSCLC.27 None of the patients had overlapping mutations.